Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals is a clinical stage neuroscience biotech developing new chemical entities (NCEs) that target the root causes of psychiatric diseases.

Brain and money connected by a thread on a white background

Biotech

AbbVie inks $1.2B deal to buy Gilgamesh's psychedelic program

AbbVie has written the next chapter in its quest to treat psychiatric disorders, agreeing to buy a psychedelic drug candidate for up to $1.2 billion.

Nick Paul Taylor Aug 25, 2025 9:42am

Fierce Pharma

AbbVie will continue to pursue external innovation for long-term

Jul 31, 2025 11:44am

AbbVie in talks over $1B Gilgamesh buyout: report

Jul 31, 2025 7:48am

Gilgamesh links psychedelic to 94% remission rate in depression

May 27, 2025 11:00am

Introducing Fierce Biotech's 2024 Fierce 15

Aug 5, 2024 6:00am